Clinical Trials Logo

ALK Gene Mutation clinical trials

View clinical trials related to ALK Gene Mutation.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04849273 Terminated - Clinical trials for Non-Small Cell Lung Cancer

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).